Hichip Pharmaceuticals Reports Positive Phase IIa Results for Fatty Liver Drug

HuiChuang Pharmaceutical announced on November 11, 2026, that its experimental drug HP515 has successfully met its primary and secondary goals in a Phase IIa clinical trial. The study focused on patients suffering from metabolic-related fatty liver disease. This condition is a growing concern for global public health as it can lead to severe liver damage over time. The trial results provide a potential new path for treating this complex metabolic disorder. Researchers observed that patients taking the oral tablet once daily experienced a notable improvement in their condition. The study measured the reduction of liver fat content, known as LFC, over a 12-week period. Participants in the various dosage groups saw an average LFC reduction of more than 50 percent. In contrast, the group receiving a placebo showed a reduction of only 3.5 percent. These findings indicate that the drug has a statistically significant effect compared to the placebo. The company noted that the trial was designed to test both the safety and the effectiveness of the medication. By targeting metabolic pathways, the drug aims to address the underlying causes of fat accumulation in the liver. This approach is distinct from treatments that only manage the symptoms of the disease. The clear difference in outcomes between the drug and placebo groups suggests that HP515 could be a viable therapeutic option. Further clinical development will be necessary to confirm these early results in larger patient populations. The company plans to use this data to design future studies that will evaluate the long-term impact of the treatment. Such trials are essential to ensure the drug remains safe and effective for patients over extended periods. If subsequent phases are successful, the medication could eventually provide a new standard of care for those living with fatty liver disease.